Investor Presentation
Novo NordiskⓇ
48
Investor presentation First six months of 2022
Two fixed dose combinations entered phase 2 in the second half
of 2021 in people with type 2 diabetes
Phase 2 trial design for cagrilintide in combination with
semaglutide investigated in T2D
Phase 2 trial design for semaglutide in combination with GIP
Randomisation
(1:1:1)
90 participants
↓
with T2D
.
HbA1c 7.5-
10.5%
⚫ Met +/- SGLT2i
•BMI >27 kg/m2
Cagrilintide QW + Semaglutide QW
Cagrilintide QW + placebo QW
Semaglutide QW + placebo QW
k-
--+------
Dose escalation
16 weeks
Treatment maintenance
16 weeks
FU 5
weeks
~500 participants
with T2D
Age ≥ 18-75
years
⚫ BMI: 25-39.9
kg/m2
⚫HbA1c: 7.0-10.0%
Diet/exercise +
metformin
Dose ratio 1:1 Semaglutide QW + GIP QW
Placebo
Dose ratio 1:3 Semaglutide QW + GIP QW
Placebo
Dose ratio 1:5 Semaglutide QW + GIP QW
Placebo
Dose ratio 1:9 Semaglutide + GIP QW
Placebo
GIP QW
Semaglutide QW
Dose escalation
10 weeks
Maintenance period
24 weeks
FU 5
weeks
Trial objective: Compare the effect on glycaemic control and body weight of
cagrilintide in combination with semaglutide vs semaglutide in patients with
T2D
Primary endpoint: Change in HbA1c (%-point)
Next steps: 37-week trial was initiated in Q3 2021
Trial objective: Compare the effect on glycaemic control and body weight of
semaglutide in combination with GIP vs semaglutide and vs GIP
Primary endpoint: Change from baseline to week 34 in HbA1c (%-point)
Trial start: 39-week trial was initiated in Q4 2021
T2D: Type 2 diabetes; HbA₁: Hemoglobin A1c; BMI: Body mass index; FU: Follow-up; OAD: Oral anti-diabetic; GIP: Gastric inhibitory peptide; QW: Once-weeklyView entire presentation